Protagonist Therapeutics, Inc. $PTGX Stock Holdings Trimmed by Aviva PLC

Aviva PLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 28.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,435 shares of the company’s stock after selling 3,765 shares during the quarter. Aviva PLC’s holdings in Protagonist Therapeutics were worth $521,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. FNY Investment Advisers LLC acquired a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $27,000. Bessemer Group Inc. increased its stake in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares during the last quarter. CWM LLC raised its holdings in shares of Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after purchasing an additional 407 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Protagonist Therapeutics by 141.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company’s stock worth $59,000 after purchasing an additional 710 shares during the period. Finally, Brooklyn Investment Group bought a new position in shares of Protagonist Therapeutics in the 1st quarter worth about $68,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $81.62, for a total transaction of $979,440.00. Following the sale, the director directly owned 5,130 shares in the company, valued at approximately $418,710.60. The trade was a 70.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 20,000 shares of company stock worth $1,473,440. 4.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PTGX has been the subject of a number of recent research reports. Johnson Rice set a $112.00 price objective on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. JMP Securities increased their price target on Protagonist Therapeutics from $67.00 to $69.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 7th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup boosted their price objective on Protagonist Therapeutics from $96.00 to $98.00 and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.23.

Protagonist Therapeutics Price Performance

Shares of Protagonist Therapeutics stock opened at $83.24 on Friday. Protagonist Therapeutics, Inc. has a 1-year low of $33.31 and a 1-year high of $93.25. The business’s fifty day moving average price is $70.57 and its two-hundred day moving average price is $58.56. The company has a market capitalization of $5.20 billion, a P/E ratio of 134.26 and a beta of 2.22.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. On average, research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.